Physician profile
Alan J Kanouff
NPI 1487787131
$809,484.28
in general payments reported to CMS, 2019-2025
55 companies · $193K in 2025
The $193K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $50K · 2021: $69K · 2022: $87K · 2023: $196K · 2024: $188K · 2025: $193K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $481K · Travel and Lodging: $37K · Honoraria: $27K · Food and Beverage: $23K · Consulting Fee: $7,831 · Education: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $480,665.50 |
| Travel and Lodging | $37,161.56 |
| Honoraria | $27,487.50 |
| Food and Beverage | $23,286.79 |
| Consulting Fee | $7,831.00 |
| Education | $368.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $529,867.92 | 2019-2025 | Breztri, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $179,453.00 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Eisai INC. | $18,798.18 | 2020-2022 | |
| Verona Pharma, INC. | $18,580.95 | 2025 | Ohtuvayre |
| Amgen INC. | $17,810.62 | 2022-2025 | Tezspire |
| Mylan Specialty L.P. | $16,787.12 | 2019-2024 | Yupelri |
| Axsome Therapeutics, INC. | $12,530.86 | 2023-2025 | Sunosi |
| Genentech USA, INC. | $5,155.58 | 2019-2025 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $984.23 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Jazz Pharmaceuticals INC. | $878.13 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $726.60 | 2019-2025 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $643.02 | 2019-2025 | Dupixent |
| Novo Nordisk INC | $553.91 | 2019-2023 | Wegovy |
| Electromed, INC. | $484.94 | 2019-2025 | Smartvest |
| United Therapeutics Corporation | $470.35 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $465.82 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $448.16 | 2020-2024 | |
| Harmony Biosciences LLC | $391.05 | 2020-2025 | Wakix |
| Ethicon INC. | $334.23 | 2022 | |
| Gilead Sciences, INC. | $323.80 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $306.89 | 2020-2025 | Glassia |
| Resmed Corp | $303.24 | 2019-2025 | |
| Insmed, INC. | $300.88 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $277.82 | 2019-2025 | Prolastin-C Liquid |
| Pfizer INC. | $268.00 | 2019-2021 | |
| Philips North America LLC | $240.63 | 2020-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Inspire Medical Systems, INC. | $194.43 | 2023-2025 | Inspire |
| Merck Sharp & Dohme LLC | $192.71 | 2019-2025 | Belsomra, Winrevair, Keytruda |
| Baxter Healthcare | $147.93 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Novartis Pharmaceuticals Corporation | $145.88 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $136.13 | 2020-2024 | Acthar |
| Avadel Cns Pharmaceuticals, LLC | $127.00 | 2024-2025 | Lumryz |
| Advanced Respiratory, INC | $120.80 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $98.99 | 2023 | |
| Paratek Pharmaceuticals, INC. | $94.66 | 2023-2025 | Nuzyra |
| Abbvie INC. | $92.71 | 2021-2024 | |
| Kvk-Tech, INC. | $81.93 | 2020-2021 | |
| Zoll Respicardia, INC. | $81.41 | 2022 | |
| Lilly USA, LLC | $67.87 | 2025 | Zepbound |
| Allergan, INC. | $56.05 | 2020 | |
| Viatris Specialty LLC | $55.76 | 2025 | Yupelri |
| Vifor Pharma, INC. | $54.55 | 2024-2025 | Zemaira |
| Idorsia Pharmaceuticals US INC | $48.36 | 2023 | Quviviq |
| Pulmonx Corporation | $45.90 | 2019-2024 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Shire North American Group INC | $39.84 | 2019 | |
| Csl Behring | $33.64 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $32.66 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $27.66 | 2025 | Purified Cortrophin Gel |
| Vapotherm INC | $23.04 | 2022 | |
| Tactile Systems Technology INC | $20.71 | 2025 | Nimbl, Flexitouch Plus |
| Seqirus USA INC | $19.48 | 2025 | Fluad, Flucelvax |
| Circassia INC. | $15.36 | 2020 | |
| Alexion Pharmaceuticals, INC. | $14.79 | 2020 | |
| Optinose US, INC. | $14.52 | 2021 | |
| Currax Pharmaceuticals LLC | $13.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Kanouff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.